| [1] |
Zeng L, Yan J, Luo L，et al. Preparation and characterization of (-)-epigallocatechin-3-gallate (EGCG)-loaded nanoparticles and their inhibitory effects on Human breast cancer MCF-7 cells[J]. Sci Rep，2017，28(7)：45 521.
|
| [2] |
Kushi LH, Doyle C, Mccullough M，et al. American Cancer Society guidelines on nutrition and physical activity for cancer prevention: reducing the risk of cancer with healthy food choices and physical activity[J]. CA Cancer J Clin，2012，62(1): 30-67.
|
| [3] |
Khan N, Afaq F, Mukhtar H. Cancer chemoprevention through dietary antioxidants: progress and promise[J]. Antioxid Redox Signal，2008，10(3)：475-510.
|
| [4] |
Mukherjee S, Ghosh S, Das D，et al. Gold-conjugated green tea nanoparticles for enhanced anti-tumor activities and hepatoprotection--synthesis，characterization and in vitro evaluation[J]. J Nutr Biochem，2015，26(11): 1283-1297.
|
| [5] |
Xu P, Yan F, Zhao Y，et al. Green tea polyphenol EGCG attenuates MDSCs-mediated immunosuppression through canonical and non-canonical pathways in a 4T1 murine breast cancer model[J]. Nutrients，2020，12(4): 1042.
|
| [6] |
Zan L, Chen Q, Zhang L，et al. Epigallocatechin gallate (EGCG) suppresses growth and tumorigenicity in breast cancer cells by downregulation of miR-25[J]. Bioengineered，2019，10(1): 374-382.
|
| [7] |
Musial C, Kuban-Jankowska A, Gorska-Ponikowska M. Beneficial properties of green tea catechins[J]. Int J Mol Sci，2020，21(5): 1744.
|
| [8] |
Li Y, Buckhaults P, Cui X，et al. Combinatorial epigenetic mechanisms and efficacy of early breast cancer inhibition by nutritive botanicals[J]. Epigenomics，2016，8(8): 1019-1037.
|
| [9] |
Steed KL, Jordan HR, Tollefsbol TO. SAHA and EGCG promote apoptosis in triple-negative breast cancer cells，possibly through the modulation of cIAP2[J]. Anticancer Res，2020，40(1): 9-26.
|
| [10] |
Song X, Zhang M, Chen L，et al. Bioinformatic prediction of possible targets and mechanisms of action of the green tea compound epigallocatechin-3-gallate against breast cancer[J]. Front Mol Biosci，2017，4: 43.
|
| [11] |
Hartrick CT, Rozek RJ. Tapentadol in pain management: a μ-opioid receptor agonist and noradrenaline reuptake inhibitor[J]. CNS Drugs，2011，25(5): 359-370.
|
| [12] |
Bimonte S, Cascella M, Barbieri A，et al. Shining a light on the effects of the combination of (-)-epigallocatechin-3-gallate and tapentadol on the growth of human triple-negative breast cancer cells[J]. In Vivo，2019，33(5): 1463-1468.
|
| [13] |
Moradzadeh M, Hosseini A, Erfanian S，et al. Epigallocatechin-3-gallate promotes apoptosis in human breast cancer T47D cells through down-regulation of PI3K/AKT and telomerase[J]. Pharmacol Rep，2017，69(5): 924-928.
|
| [14] |
Lin YC, Lee YC, Li LH，et al. Tumor suppressor SCUBE2 inhibits breast-cancer cell migration and invasion through the reversal of epithelial-mesenchymal transition[J]. J Cell Sci，2014，127(Pt 1): 85-100.
|
| [15] |
Sheng J, Shi W, Guo H，et al. The inhibitory effect of (-)-epigallocatechin-3-gallate on breast cancer progression via reducing methylation and DNMT activity[J]. Molecules，2019，24(16): 2899.
|
| [16] |
Wang Z, Zhang X, Shen P，et al. A variant of estrogen receptor-{alpha}，hER-{alpha}36: transduction of estrogen- and antiestrogen-dependent membrane-initiated mitogenic signaling[J]. Proc Natl Acad Sci USA，2006，103(24): 9063-9068.
|
| [17] |
Shi L, Dong B, Li Z，et al. Expression of ER-{alpha}36，a novel variant of estrogen receptor {alpha}，and resistance to tamoxifen treatment in breast cancer[J]. J Clin Oncol，2009，27(21): 3423-3429.
|
| [18] |
Pan X, Zhao B, Song Z，et al. Estrogen receptor-α36 is involved in epigallocatechin-3-gallate induced growth inhibition of ER-negative breast cancer stem/progenitor cells[J]. J Pharmacol Sci，2016，130(2): 85-93.
|
| [19] |
Li Y, Meeran SM, Tollefsbol TO. Combinatorial bioactive botanicals re-sensitize tamoxifen treatment in ER-negative breast cancer via epigenetic reactivation of ERα expression[J]. Sci Rep，2017，7(1): 9345.
|
| [20] |
Shin S, Kim MK, Jung W，et al. (-)-Epigallocatechin gallate derivatives reduce the expression of both urokinase plasminogen activator and plasminogen activator inhibitor-1 to inhibit migration，adhesion，and invasion of MDA-MB-231 cells[J]. Phytother Res，2018，32(10): 2086-2096.
|
| [21] |
Riley RS, June CH, Langer R，et al. Delivery technologies for cancer immunotherapy[J]. Nat Rev Drug Discov，2019，18(3): 175-196.
|
| [22] |
Kumar V, Patel S, Tcyganov E，et al. The nature of myeloid-derived suppressor cells in the tumor microenvironment[J]. Trends Immunol，2016，37(3): 208-220.
|
| [23] |
Parker KH, Beury DW, Ostrand-Rosenberg S. Myeloid-derived suppressor cells: critical cells driving immune suppression in the tumor microenvironment[J]. Adv Cancer Res 2015，128: 95-139.
|
| [24] |
Corzo CA, Cotter M, Cheng P，et al. Mechanism regulating reactive oxygen species in tumor-induced myeloid-derived suppressor cells[J]. J Immunol，2009，182(9): 5693-5701.
|
| [25] |
Chen J, Ye Y, Liu P，et al. Suppression of T cells by myeloid-derived suppressor cells in cancer[J]. Hum Immunol，2017，78(2): 113-119.
|
| [26] |
Zhao W, Mackenzie GG, Murray OT，et al. Phosphoaspirin (MDC-43)，a novel benzyl ester of aspirin，inhibits the growth of human cancer cell lines more potently than aspirin: a redox-dependent effect[J]. Carcinogenesis，2009，30(3): 512-519.
|
| [27] |
Wei R, Mao L, Xu P，et al. Suppressing glucose metabolism with epigallocatechin-3-gallate (EGCG) reduces breast cancer cell growth in preclinical models[J]. Food Funct，2018，9(11): 5682-5696.
|
| [28] |
Pouysségur J, Dayan F, Mazure NM. Hypoxia signalling in cancer and approaches to enforce tumour regression[J]. Nature，2006，441(7092): 437-443.
|
| [29] |
Deng D, Xu C, Sun P，et al. Crystal structure of the human glucose transporter GLUT1[J]. Nature，2014，510(7503): 121-125.
|
| [30] |
Mulliez T, Veldeman L, Van Greveling A，et al. Hypofractionated whole breast irradiation for patients with large breasts: a randomized trial comparing prone and supine positions[J]. Radiother Oncol，2013，108(2): 203-208.
|
| [31] |
Zhu W, Jia L, Chen G，et al. Epigallocatechin-3-gallate ameliorates radiation-induced acute skin damage in breast cancer patients undergoing adjuvant radiotherapy[J]. Oncotarget，2016，7(30): 48 607-48 613.
|
| [32] |
Zhao H, Zhu W, Jia L，et al. Phase I study of topical epigallocatechin-3-gallate (EGCG) in patients with breast cancer receiving adjuvant radiotherapy[J]. Br J Radiol，2016，89(1058): 2015 0665.
|
| [33] |
Radhakrishnan R, Pooja D, Kulhari H，et al. Bombesin conjugated solid lipid nanoparticles for improved delivery of epigallocatechin gallate for breast cancer treatment[J]. Chem Phys Lipids，2019，224: 104 770.
|
| [34] |
Radhakrishnan R, Kulhari H, Pooja D，et al. Encapsulation of biophenolic phytochemical EGCG within lipid nanoparticles enhances its stability and cytotoxicity against cancer[J]. Chem Phys Lipids，2016，198: 51-60.
|
| [35] |
Yi Z, Chen X, Chen G，et al. General nanomedicine platform by solvent-mediated disassembly/reassembly of scalable natural polyphenol colloidal spheres[J]. ACS Appl Mater Interfaces，2020，12(34): 37 914-37 928.
|
| [36] |
Liang T, Yao Z, Ding J，et al. Cascaded aptamers-governed multistage drug-delivery system based on biodegradable envelope-type nanovehicle for targeted therapy of HER2-overexpressing breast cancer[J]. ACS Appl Mater Interfaces，2018，10(40): 34 050-34 059.
|
| [37] |
Samavat H, Ursin G, Emory TH，et al. A randomized controlled trial of green tea extract supplementation and mammographic density in postmenopausal women at increased risk of breast cancer[J]. Cancer Prev Res(Phila)，2017，10(12): 710-718.
|